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ABSTRACT  Three monoclonal  antibodies that react with  previously undefined  antigenic de- 
terminants  on  the  clathrin  molecule  have been produced  and  characterized.  They  were 
isolated from a fusion between myeloma cells and popliteal lymphocytes from SJL mice that 
had received footpad  injections  of human brain clathrin. This protocol  was chosen to favor 
the  production  of  antibodies  to  poorly  immunogenic  proteins  and  thereby  increase the 
repertoire  of anti-clathrin  monoclonal  antibodies.  One antibody (X16) reacts preferentially 
with the heavier of the two clathrin  light chains (LCa) when it is not associated with  heavy 
chain.  This specificity  is  different  from  that  of the  anti-LCa antibody,  CVC.6, which  has 
preferential  reactivity  with  heavy chain-associated  LCa. In addition,  X16 and CVC.6 bound 
simultaneously to LC,, confirming that they react with different sites. The other two antibodies 
produced,  X19 and X22, react with two different  determinants on the clathrin  heavy chain, 
based on immunoprecipitation,  Western blot, and binding studies. Competitive binding studies 
with  anti-clathrin  monoclonal  antibodies  showed  that  they  define  a total  of  five  distinct 
antigenic determinants on bovine clathrin. 
Endocytosis and  biosynthesis of membrane-bound and  se- 
creted proteins are accompanied by membrane translocation 
(1).  During  these  processes, closed membrane vesicles that 
contain  internalized receptors and ligands or newly synthe- 
sized glycoproteins are formed within the cytoplasm (2,  3). 
These vesicles are surrounded by a polyhedral network of the 
protein, clathrin, and are therefore known as coated vesicles 
(4, 5). At the cell surface, assembly of clathrin into a mem- 
brane-associated network occurs simultaneously with mem- 
brane invagination, forming a coated pit (6). This circumstan- 
tial evidence, combined with the fact that purified clathrin 
will  form a  closed polyhedral structure under certain  ionic 
conditions, suggests  that clathrin assembly is essential to the 
mechanics  of membrane translocation.  (7-11).  Clathrin  is 
composed of three polypeptides, a heavy chain of 180 kD and 
two light chains, LCa and LCb, of 32-38  kD, depending on 
the tissue of origin (5, 9-11,  12). The LCa light chain is 2-3 
kD greater than the LC~ light chain. The light chains of brain 
clathrin are both of higher molecular weight than those in 
nonbrain tissue such that brain LCb has approximately the 
same molecular weight as LCa from other tissues (12). Clathrin 
can be removed from isolated coated vesicles by treatment 
with high pH or high concentrations of Tris or urea (8-10). 
Further fractionation by size-exclusion chromatography has 
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demonstrated that clathrin heavy and light chains co-purify 
in  a  unit  composed of three  heavy chains  and three  light 
chains. Electron microscopy studies have shown that this unit 
has a  distinct morphology. It resembles a  three-legged pin- 
wheel, known as a triskelion, which is geometrically favorable 
for  forming the  pentagons  and  hexagons  characteristic  of 
assembled clathrin polyhedra (9-11). 
Production of monoclonal antibodies (MAbs) ~ to clathrin 
has already proved an informative approach to understanding 
structure-function relationships between the clathrin  mole- 
cule, clathrin assembly, and membrane translocation. MAbs 
to a determinant on the LCa light chain were used by Kirch- 
hausen et al. to localize the position of this light chain on the 
clathrin triskelion to the portion of the triskelion leg proximal 
to the vertex (13). The same MAbs were used by Brodsky and 
Parham  (12)  to  investigate the  polymorphism of the  light 
chains in different tissues and by Holmes et al. (14) to purify 
separated LCa and LCb from brain and adrenal glands and 
compare their primary structure by peptide mapping. Lou- 
vard et al. (15) have produced a MAb that reacts with clathrin 
heavy chain  which  has been  used  in  immunofluorescence 
studies to demonstrate the existence of a pool of unpolymer- 
1  Abbreviations used in this paper. MAb, monoclonal antibody; RIA, 
radioimmunoassay. 
2047 ized clathrin within a cell. Kelly et al.  (16) have used MAbs 
to bovine brain clathrin LCa and to chicken coated vesicles 
to demonstrate the association of tubulin with coated vesicles. 
One noticeable feature of these studies is the limited number 
of antibodies  used.  Even  more  limited  is  the  number  of 
different antigenic determinants that have been defined  on 
the clathrin molecule, suggesting that clathrin may be a poorly 
immunogenic antigen. This is further supported by the weak 
binding properties of the MAbs that have been produced. The 
anti-heavy chain MAb is of the IgM isotype characterized by 
low affinity individual  binding  sites (15).  Its broad species 
cross-reactivity is probably a  result of enhanced avidity ac- 
quired from the  l0 antigen combining sites on an IgM mol- 
ecule. The anti-LCa  MAbs are of the IgG isotype and have a 
binding site affinity that makes them useful in biochemical 
studies (13). However, their avidity is low and they react only 
with bovine clathrin. 
This paper describes the production and characterization 
of  IgG  monoclonal antibodies  that  react  with  two  newly 
defined antigenic determinants on clathrin heavy chain and 
one  new determinant on  the  LCa light chain.  These  three 
MAbs react with both human and bovine clathrin. They were 
produced following an immunization procedure designed to 
overcome poor anfigenicity. Human clathrin was used as an 
antigen so that resulting antibodies might eventually be used 
to study clathrin-mediated processes in human cell lines in 
which  many receptors have also been  defined  with MAbs. 
During the characterization of these new MAbs, their speci- 
ficity was compared with the specificity of two existing anti- 
clathrin antibodies to determine the total number of antigenic 
sites thus far defined on the clathrin molecule. 
MATERIALS  AND  METHODS 
Monoclonal Antibody Production (17) 
Five female SJL mice were immunized  with purified human brain clathrin 
by the injection into each footpad of 5 ug in complete Freund's adjuvant  on 
day 17, 5 ug in incomplete Freund's adjuvant on day 14, and l0 ~tg in 0.5 Tris, 
0.05 M 2-(N-morpbolino)ethane  sulfonic acid (pH 6.2), 0.5 mM EGTA, 0.25 
mM MgCl2 on days  10, 7, 4, and  1 before fusion. On day zero the popliteal 
lymph nodes were removed,  and  the  lymph  node  cells were fused with the 
myeloma cell line SP2/0-Agl4  (18) in a ratio of 2:1, according to the method 
of Galfr~ et  al.  (19). Resulting  hybridoma  cell lines  were cloned  twice by 
limiting dilution.  Cell lines were grown in ascites fluid of irradiated  (300 rad) 
BALB/c mice, injected with 0.5  ml 2,6,10,14-tetramethyl-pentadecane  (pris- 
tane) before cell passage. Antibody was purified from ascites fluid by ammo- 
nium sulfate precipitation  and chromatography  on Sephadex G-200, as previ- 
ously  described  (20). Isotyping  was carried  out with  a  kit  from  Southern 
Biotechnology Associates (Birmingham, AL). 
Radioimmunoassays (RIA) 
IODINATION"  Monoclonal  antibodies or affinity purified anti-immuno- 
globulin antibody (25 #g in 100 #l 0.3 M phosphate buffer, pH 7.4) were labeled 
with  l  mCi  ~251-Nal (IMS.30,  Amersham Corp.,  Arlington  Heights,  IL) by 
incubation  with one lodo-bead  (No.  28660, Pierce Chemical Co.,  Rockford, 
IL) for 5 rain at room temperature.  Free iodine was removed by gel filtration 
over a  10-ml column of Sephadex G-50 (medium) equilibrated in phosphate- 
buffered saline, pH 7.4, with 0.5% bovine serum albumin (PBS/BSA). 
INDIRECT  SOLID-PHASE  RIA (21):  Clathrin, clathrin components,  or 
coated vesicles (50-500  #g/ml in PBS) were applied to the wells of polyvinyl 
chloride  microtiter  plates, 20 #l/well.  After  l  h at room temperature,  plates 
were washed twice in PBS/BSA, and 200 ~l PBS/BSA was left in the wells for 
I  h  at  room temperature  and  removed.  Antibodies  as  hybridoma  culture 
supernatant  or purified at 20 #g/ml in PBS/BSA were then added to the wells 
(20 #l/well) and incubated  for I h at 4"C. After three washes in PBS/BSA, 20 
#l of t251-F(ab')2 of rabbit anti-mouse  immunoglobulin  was added to the wells 
and incubated for 1 h, 4"C. Plates were then washed four times, and wells were 
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counted for radioactivity bound. 
SANDWICH  RIA  (22):  Monoclonal  antibody  (100 ug/ml in PBS) was 
applied to the wells of polyvinyl chloride microtiter plates, 20 ul/well, for 1 h 
at room temperature,  and binding  sites were blocked with PBS/BSA as de- 
scribed above. Serial dilutions of  purified antigen in PBS/BSA were then added, 
50 ul/weU, along with a second ~2SI-labeled monoclonal antibody (6 x  l05 cpm/ 
20 ul per well). After overnight incubation  at 4"C with agitation, plates were 
washed four times with PBS/BSA, and wells were counted  for radioactivity 
bound. 
COMPETITION RIA  (20):  Purified clathrin  was applied to the wells of 
polyvinyl chloride plates as described for the indirect solid-phase RIA, and then 
blocked with BSA. Monoclonal  antibodies,  starting at concentrations  of 100 
~g/ml, were serially diluted, and 20 td of each dilution was added to clathrin- 
coated plates. Atier incubation for 1 h at 4"C, ~2SI-labeled monoclonal antibodies 
were added directly to these wells and incubated for 30 rain at 4"C. Plates were 
then washed four times and wells were counted  for radioactivity bound.  J2~I- 
labeled monoclonal antibodies were titered in advance for binding to clathrin 
in a solid-phase RIA to select a dilution that did not saturate the clathrin bound 
and would therefore be sensitive to blocking by unlabeled antibody. 
Electrophoresis 
SDS PAGE was carried out according to the method  of Laemmli (23). All 
gels shown contain  10% acrylamide. Gels were stained with 0.2% Coomassie 
Brilliant Blue R in 9.5% acetic acid, 45.5% methanol  in water, and destained 
with 10% acetic acid, 40% methanol in water. Gels were treated with Enlight- 
ening (New England Nuclear, Boston, MA), dried, and exposed to XAR-5 film 
using an intensifying screen (Dupont Lightening Plus, DuPont Photo Products 
Division-X-Ray, Burbank, CA) when autoradiography was required. 
Western blotting was carried out as previously described with one modifi- 
cation  (20). Whole  gels with  duplicate  sets of samples  were  transferred  to 
nitrocellulose. After transfer, the nitrocellulose was stained with Amido black 
and then cut into strips for separate incubation with antibodies or retention as 
a control stained for protein. Cell lysate samples were prepared by incubation 
of 2 x  l07 cells/ml in 0.5% Nonidet P-40, l0 mM Tris, pH 7.3, I mM MgCI2 
for 30 min at 4"C and then centrifuged in a microfuge for l0 min (24). 20 ul 
of the resulting supernatant  was applied to the gel. 
Molecular weight marker proteins  used on all gels were from Pharmacia 
Fine Chemicals (Piscataway, N  J). They include phosphorylase b (94 kD), BSA 
(67 kD),  ovalbumin  (43  kD),  carbonic  anhydrase  (30  kD),  soybean trypsin 
inhibitor (20.1 kD), and a-lactalbumin  (14.4 kD). 
Immunochemistry 
Immunoprecipitation  using fixed Staphylococcus aureus bacteria was carried 
out as described by Parham and Ploegh (24). For each reaction, 5 ug purified 
monoclonal  antibody  was incubated  with  106 cpm of 3H-labeled clathrin  or 
3H-labeled light chains.  Rabbit  anti-mouse  Ig serum was added  to facilitate 
fixed S. aureus bacteria binding. 
Affinity chromatography was according to the method of Parham  using 50 
mM diethylamine,  pH  11.5, to elute the affinity columns (25). Monoclonal 
antibodies were coupled to CNBr-activated Sepharose 4B from Pharmacia Fine 
Chemicals according to the instructions  except that the coupling reaction was 
carried out for 10 rain.  MAbs were coupled to CNBr-activated Sepharose 2B 
at pH 7.0 following the procedure of March et al. (26). 
Purification of Clathrin, Clathrin Components, 
and Coated Vesicles 
Clathrin was purified from human and bovine brain by extraction of  a crude 
membrane preparation  with 0.75 M Tris, 0.025 M 2-(N-morpholino)etbane 
sulfonic acid (pH 6.2), 0.25 mM EGTA, 0.12 mM MgCl2, and then ammonium 
sulfate precipitation and chromatography on Sepharose 4B-CL were performed 
as previously described (27). 
Clathrin light chains were isolated by heating purified clathfin to 100*C for 
l0 min. The denatured  heavy chain was removed by centrifugation at 35,000 
g for 30 rain (14). Purified light chains were dialyzed into PBS, and LCo was 
separated  from LCb by affinity chromatography  on a  CVC.6-Sepharose 4B 
column (1.5 x 5 cm). CVC.6 is an LC,-specific MAb (13). The column retained 
~30 ~g LCJml, which was eluted using 50 mM diethylamine,  pHI 1.5, then 
dialyzed into PBS, and centrifuged before use. The effluent consisted of -80% 
pure LCb. 
Clathrin  heavy chain was isolated after chromatography  of clathrin  in  1.3 
M potassium thiocyanate  on a column of AcA 34 (1  x  25 cm), according to 
the method of Winkler and Stanley (28). Fractions were dialyzed into 50 mM Tris (pH 8.0), 50 mM NaCl,2mM EDTA, I mM dithiothreitol, and analyzed
by SDSPAGE and indirect RIA for reactivity with the anti-LC, MAb,CVC.6 .
The heavy chain-containing fractions with no antibody reactivity were pooled
for use .
Humanlymphoid coated vesicles were purified from 10'LB cellsas described
by Kinnon andOwen (29) using the deuterium oxide gradient method ofPearse
(30) .
Purified clathrin and purified clathrin light chains were radioactively labeled
by reductive methylation according to the method of Tack et al . (31) as
described by Schlossman et al . (32) . Specific activities were 106 cpm/t<g for
clathrin and6 x 10' cpm/tug for the light chains.
Cells, Media, andAntibody Reagents
The Anti-Leu 10 antibody (22) and the anti-Igh5b antibody (33), used as
control antibodies of the IgG, isotype, react with HLA-DQ glycoproteinson
the surface of human lymphocytes and mouse IgD, respectively . They were
obtained in purified form from Becton DickinsonImmunocytometry Systems .
The retinoblastoma cell line, Y79, and the neuroblastoma cell line, 134H, were
a gift from D . Buck (Becton Dickinson Monoclonal Center, Mountain View,
CA) and were maintained in RPMI 1640 with 10% fetal calf serum and
passagedwith 0.25% trypsin-EDTA (No. 610-5300, Gibco Laboratories, Grand
Island, NY). The adenocarcinoma cell line LS184T and the 3T3 mouse cell
line were obtained from the American Type CultureCollection (Bethesda, MD)
and maintained according to instructions . The LB cell line, an Epstein-Barr
virus-transformed human B cell line, a gift from V . Engelhard (University of
Virginia, Charlottesville), was maintained in RPMI 1640 with 10% fetal calf
serum .
RESULTS
Strategy for Anti-Clathrin MAb Production
To produce MAbs that reacted with human clathrin, clath-
rin was purified fromhuman brain tissue by the same method
used to isolate bovine brain clathrin . Purified human brain
clathrin was then injected every 3 d into the footpads of SJL
mice (5-10 Ag/footpad, six injections) . Lymphocytes from
the popliteal lymph nodes of the immunized mice were fused
with the SP2 myeloma cell line. 10 MAbs were isolated from
this fusion . Initial specificity tests included solid-phase RIA,
immunoprecipitation and Western blotting . These suggested
that two of the MAbs (X19 and X22) had specificity for
different determinants on the clathrin heavy chain . Three
(represented by X 16) had similar reactivity with the LC, light
chain and probably originated from the same expandedB cell
clone. These MAbs all expressed the IgG i isotype . The re-
maining five antibodies reacted with minor contaminants in
the human clathrin preparation that did not correlate with
any of the known clathrin-associated proteins and were not
investigated further in this study . Fig. 1 shows the results
obtained when the X 16, X 19, and X22 MAbs were tested for
reactivity with different types of clathrin and separated Clath-
rin polypeptides in solid-phase RIA . They were compared
with CVC.4 and CVC.6, representing the two types of anti-
clathrin MAbs produced in a previous set of experiments .
Interpretation of the chain specificities of these MAbs is
slightly complicated by the fact that small amounts of LC.
were present in the LCb preparation . However, it is clear that
CVC.6 and X16 are specific for the LC. light chain and that
X19 and X22 react with heavy chain . The polypeptide spec-
ificity of theCVC.4 antibody is still ambiguous .
LC a-specific Antibodies
Western blot analysis (Fig . 2) showed that X16 reacts with
bovine and human clathrin LCa, as suggested by the RIA in
Fig . 1 . The specificity of CVC.6 for bovine clathrin LCa has
been previously demonstrated by Western blotting (13). The
FIGURE 1
￿
Test of MAb reactivity with clathrin, clathrin polypep-
tides, and coated vesicles (CV's) by indirect solid-phase RIA. The
antigens listed at the lower right corner of the figure were applied
to the wells of a polyvinyl chloride plate . The antibodies indicated
in each panel were incubated in the wells of these plates, and
antibody binding was detected by subsequent binding of "'I-anti-
immunoglobulin . Each bar represents antibody binding to the an-
tigen numbered at the left. Bars are the mean of duplicate assays .
Background binding (the mean of duplicate assays with a control
antibody binding to the same antigen) is subtracted . Antigens 3 and
7 are pools of LC, and LCb produced by boiling and centrifugation
of triskelions . Antigens 4 and S were separated by immunoaffinity
chromatography .
clathrin light chains havebeen shown to be extremely sensitive
to proteolysis, and proteolytic fragments ofLC a are frequently
present in clathrin preparations (9, 14) . One of these LCa
fragments co-migrates upon SDS PAGE with LCb and has
been confirmed by peptide mapping to be derived completely
from LC, (14) . Another LC a fragment migrates slightly faster
than LCb and reacts with the CVC.6 MAb (13) . The Western
blots in Fig. 2 show that X16 reacts with LC, and both of
these LC. fragments in preparations of bovine and human
brain clathrin (Fig . 2, lanes A and B). It also reacts with four
or five smaller proteolytic fragments ofLC,, . Partially purified
clathrin in lymphoid coated vesicles and clathrin in crude
tissue extracts has been subjected to less manipulation and
consequently less opportunity for proteolysis . In such prepa-
rationsX 16 binding detects LC. at its native molecular weight
(Fig. 2, lanesC E-H, K) . Note that the LCa in these prepa-
rations is of the lower molecular weight typical of nonbrain
tissue . This is expected for the cells oflymphoidand endocrine
origin but somewhat surprising for retinoblastoma and neu-
roblastoma cells, which are derived from brain-like tissue .
This suggests that these tumor cells no longer make brain-
type clathrin or that the tumors arose from a minor popula-
tion of non-neuronal cells in the tissue . The Western blot in
Fig . 2 also shows that X 16 reacts with LC. from a mouse cell
line (lane K) and is, therefore, an autoantibody. This LCa is
of slightly higher molecular weight than human clathrin LCa
in nonbrain tissue .
To confirm that X16 reacts exclusively with LCa from brain
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2049FIGURE 2  Test  of MAb reactivity 
with  purified  brain  clathrins, 
lymphoid  coated  vesicles,  and 
cell line extracts by Western blot. 
Protein samples were applied to 
polyacrylamide gels  in  multiple 
identical  sets and  subjected  to 
SDS PAGE. After electrophoretic 
transfer to nitrocellulose, one set 
of  samples  was  stained  with 
Amido black to detect total pro- 
tein.  After the other transferred 
samples  were  reacted  with  the 
antibody  indicated,  12Sl-anti-im- 
munoglobulin was  added.  Anti- 
body binding was detected by au- 
toradiography. Samples analyzed 
are  as  follows:  lane  A,  bovine 
brain  clathrin;  lane  B,  human 
brain  clathrin;  lane  C,  human 
lymphoid coated vesicles; lane D, 
molecular  weight  marker  pro- 
teins;  lane E,  human  B cell line; 
lane  F,  human  adenocarcinoma 
cell  line;  lane G,  human retino- 
blastoma cell line; lane H, human 
neuroblastoma cell line; and lane 
K,  mouse  3T3  cell  line.  Those 
samples  and  markers with  the 
higher  molecular  weight  light 
chains typical of brain  tissue are 
indicated  by  an  asterisk. Other 
samples and  markers show light 
chain mobilities characteristic  of 
nonbrain tissue. Samples in lanes 
E-H  and  K are cell  lysates pre- 
pared  by  solubilization in  0.5% 
Nonidet  P-40. Identical  panels 
were reacted with control mono- 
clonal aritibodies of the same is- 
otype,  and  no  binding was  de- 
tected. 
clathrin,  purified  human  brain  clathrin  light  chains  were 
applied to an Xl6-Sepharose 2B column and to a column of 
Sepharose 2B coupled to a nonspecific MAb for comparison 
(Fig.  3). The effluent from the nonspecific column (Fig.  3, 
lanes 1-3) contained both LCa and LCb whereas the effluent 
from the Xl6 column (lanes 4-6) contained only LCb. The 
amount of effluent LCb from the X 16 column appears slightly 
lower than that from the nonspecific column. This is due to 
removal of the proteolytic fragment of LCa that co-migrates 
with  LCb and  reacts with  the  XI6  antibody. Similar X16 
affinity columns have subsequently been used to remove LCa 
from preparations of brain  clathrin light chains.  Resulting 
LCb preparations were completely devoid of contaminating 
LCa, as assessed by indirect solid-phase RIA. 
FIGURE 3  Specificity  of X16-Sepharose 2B for human brain LCa. 
Human brain light chains were prepared by boiling and centrifuga- 
tion of purified human brain clathrin. A ]-~g sample was analyzed 
electrophoretically in  lane L. A  16-#g sample of light chains was 
applied to a 0.5-ml column of X16 coupled to Sepharose 2B or anti- 
Igh5b coupled to Sepharose 2B. The latter is a control antibody of 
2050  THE  JOURNAL  OF  CELL  BIOLOGY .  VOLUME  101,  1985 
the IgG1 isotype.  Fractions (250/~l)  were collected during sample 
application, and the protein was precipitated from them with 1 ml 
cold acetone. The protein content of these fractions was analyzed 
by SDS  PAGE. Lanes 1-3  are effluent fractions  from the control 
column. Lanes 4-6 are effluent fractions  from the X16-Sepharose 
2B column. Lane S shows standard molecular weight markers. It is evident from the experiment in Fig.  1 that CVC.6 and 
X 16 have different species cross-reactivity although they both 
react with bovine clathrin LC~. Results of several additional 
experiments confirm that these two MAbs react with different 
antigenic sites  on the LC~ molecule. The X16  and CVC.6 
MAbs  were  tested  for  their  ability  to  immunoprecipitate 
bovine brain  clathrin (triskelions) or isolated bovine brain 
clathrin light chains that were labeled by reductive methyla- 
tion. As seen in Fig. 4, the CVC.6 antibody immunoprecipi- 
tated heavy chain in association with light chain, when reacted 
with 3H-triskelions,  and showed a weak immunoprecipitation 
reaction with 3H-light chains.  Note that the 3H-light chains 
have degraded to yield an LC~ fragment that was also precip- 
itated by CVC.6.  The CVC.6  reaction with triskelions was 
weaker than that of XI9 or X22, and the autoradiograph was 
somewhat overexposed in order to detect the triskelion-asso- 
ciated light chains  in  the  CVC.6  immunoprecipitate. This 
resulted in exaggeration of the nonspecific binding seen with 
the control antibody, Anti-Leu 10. Compared with this con- 
trol antibody,  the  XI6  MAb  showed no specific reactivity 
with 3H-triskelions.  In contrast, X16 gave a strong immuno- 
precipitation reaction with 3H-light chains, isolating LC~ and 
the LC, fragment. These results suggest that in immunopre- 
cipitation X I6 reacts preferentially with LCa when it is not 
associated with heavy chain. This is supported by the prop- 
erties of X 16 and CVC.6 antibody affinity columns. An X 16 
affinity column bound free LCa but not triskelions or coated 
vesicles. In contrast, a CVC.6 affinity column bound LCa in 
all three forms of clathrin. 
In solid-phase RIA (Fig.  1), X16 bound to coated vesicles 
and to LC, in immobilized triskelions, apparently as well as 
to free light chain. To investigate the discrepancy between 
X 16 reactivity in solid-phase RIA and immunoprecipitation, 
X l6  and  CVC.6  were tested  quantitatively for binding to 
triskelions and free light chain in a solid-phase RIA (Fig. 5A) 
or a  sandwich RIA (Fig.  5B). In the solid-phase RIA,  X16 
and CVC.6  showed little difference in their reactivity with 
either target antigen. The sandwich RIA is more sensitive to 
differences in antibody affinity because the reactions between 
the iodinated antibody and  antigen take place  in  solution. 
These antibody-antigen complexes are "captured" by the an- 
tibody on the plate only if they are sufficiently stable (34). 
Iodinated X16 antibody, complexed with free light chain, was 
bound by CVC.6. Complexes formed between iodinated X 16 
and triskelions were not stable, and no binding to CVC.6 was 
detectable. In  the reverse situation, iodinated CVC.6  com- 
plexed with triskelions bound to X 16. The iodinated CVC.6- 
free light chain complexes were less stable, and significantly 
fewer complexes bound to X 16. These results suggested that, 
in solution, X 16 has a greater affinity for free LC, than for 
heavy chain-associated LCa; CVC.6 binding demonstrates the 
opposite preference. The fact that X 16 and CVC.6 could form 
a sandwich with antigen between them confirmed that they 
were binding to distinct sites on LCa. This was also supported 
by the blocking experiments described below. 
FIGURE 4  Immunoprecipitation of ~H-clathrin triskelions and 3H- 
dathrin  light chains with anti-clathrin MAbs. Clathrin (triskelions) 
and  clathrin  light  chains  were  purified  from  bovine  brain  and 
labeled by reductive methylation. A purified MAb (5/~g) was com- 
bined with each antigen preparation (100  cpm in 25-30 ~.l). Antigen- 
antibody complexes  were  isolated  by  immunoprecipitation with 
fixed S.  aureus  bacteria,  analyzed by SDS PAGE, and immunopre- 
cipitated antigen was detected by autoradiography. Anti-Leu 10 is 
a  negative  control  with  the  same isotype as  the  test  antibodies 
(IgG1). The anti-clathrin antibodies used  are  indicated above the 
lanes that show their immunoprecipitated antigens.  The left-hand 
panel shows irnmunoprecipitates obtained with 3H-triskelions.  The 
right-hand panel shows immunoprecipitates obtained with 3H-light 
chains. 
Heavy Chain-specific Antibodies 
The two MAbs, X19 and X22, that demonstrated binding 
to separated clathrin heavy chain in solid-phase RIA (Fig.  l) 
were tested for reactivity with clathrin in Western blots. The 
X22 antibody reacted with heavy chain from bovine brain, 
human brain, and human lymphoid clathrin as shown in Fig. 
2. The X19 antibody did not react in Western blots. In the 
immunoprecipitation experiments shown in Fig.  5, X 19 re- 
acted with 3H-clathrin triskelions, producing an immunopre- 
cipitate similar to that obtained with X22, and did not im- 
munoprecipitate  antigen  from  a  preparation  of  3H-light 
chains, as seen with CVC.6. This further suggests that the Xl9 
antigenic site is present on the clathrin heavy chain. 
In  the  solid-phase  RIA  shown  in  Fig.  1,  clathrin  heavy 
chain was prepared by chromatography in the presence of 1.3 
M potassium thiocyanate. To confirm the specificity of X 19 
and X22 for heavy chain, a second method for obtaining light 
chain-free preparations of clathrin was  used,  and antibody 
binding was tested. Clathrin was exposed to mild digestion by 
elastase  or thermolysin, which proteolyze the light chains to 
small fragments, leaving the heavy chain essentially intact. 
Both the  X l9  and  X22  antibodies retained reactivity with 
clathrin treated in this way whereas the anti-LCa antibody, 
CVC.6, no longer bound. 
Quantitation of Antigenic Sites 
To investigate the question of how many antigenic sites on 
the clathrin molecule are recognized by the MAbs described 
above, a competition experiment was carried out. The Mabs 
were iodinated, and  an appropriate dilution was tested for 
reactivity with clathrin in the presence of increasing concen- 
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FIGURE  5  Comparison of X16 and CVC.6 reactivity with clathrin 
triskelions and  clathrin light chains.  (A)  Indirect solid-phase RIA: 
Purified  clathrin triskelions (lmg/ml) and light chains,  prepared by 
boiling triskelions (1  mg/ml), were diluted  1/8  in  PBS, then  five 
further twofold dilutions were made. Samples of each dilution were 
applied to polyvinyl chloride plates. These were tested for reactivity 
with the MAbs indicated (20 #g/ml) by indirect RIA, using 1251-anti- 
immunoglobulin to detect antibody binding. X22  was used  as a 
control to demonstrate that no clathrin heavy chain remained in 
the light chain preparation. (B) Sandwich RIA: Purified Xl 6 or CVC.6 
was diluted to  100 ug/ml and used to coat the wells of polyvinyl 
chloride plates. The preparations of triskelions (1  mg/ml) and light 
chains derived from them, used in A, were diluted twofold in PBS/ 
BSA 1  1 times. Dilutions of each antigen were added to wells of the 
antibody-coated plates. 1251-labeled  X16 antibody was added to the 
antigen-containing wells of plates coated with CVC.6.  ~251-1abeled 
CVC.6 antibody was added to the antigen-containing  wells of plates 
coated with X16. After overnight incubation plates were washed, 
and the binding of the iodinated antibodies was measured. Bars 
indicate the binding of the iodinated antibody to the coated plate 
in the  presence of  either triskelions or light chains.  Background 
binding of an iodinated control antibody of the same isotype was 
subtracted in  each  assay. Note that  in the left-hand panel cross- 
hatched bars indicate binding in the presence of light chains, and 
in the right-hand panel cross-hatched bars indicate binding in the 
presence of triskelions. 
trations of unlabeled antibodies (Fig. 6). As predicted above, 
the X16 and CVC.6 antibodies did not substantially block 
each other in binding to LCa, although CVC.6 binding caused 
a slight reduction in X 16 binding at high concentrations. X22 
and X19 did not block each other in binding to heavy chain. 
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All  four of these  antibodies effectively blocked their  own 
binding to clathrin. The CVC.4 antibody was most affected 
by the binding of the other antibodies. Thus far, the polypep- 
tide specificity of this antibody has been unclear. It binds to 
bovine and human clathrin in solid-phase RIA. When coupled 
to Sepharose and used as an immunoaffinity column it retains 
coated vesicles and clathrin triskelions. It does not bind to 
free clathrin light chains, although its binding to clathrin is 
sensitive to mild proteolysis. The antibody does not show any 
specificity in immunoprecipitation or Western blot, and titra- 
tion curves suggest that its affinity is quite low. This, perhaps, 
explains its sensitivity to the binding of other antibodies in 
the competition assay. CVC.4 binding was partially inhibited 
by CVC.6 and completely inhibited by X19 binding. In the 
reciprocal combination it partially inhibited CVC.6 binding 
but barely affected X19 binding. These results do not clarify 
the chain specificity of CVC.4, since CVC.6 reacts with LC~ 
and X 19 seems to be specific for heavy chain. These compe- 
tition studies indicate that five different antigenic determi- 
nants on bovine clathrin are recognized by the MAbs under 
investigation. 
DISCUSSION 
Experience with making monoclonal antibodies to clathrin 
has suggested  that the molecule is  not very immunogenic. 
Reports in the literature have described antibodies with rela- 
tively low affinity binding sites that detect a limited number 
of antigenic sites  (13,  15,  16). The first  MAbs reported to 
react with clathrin were produced by initial intraperitoneal 
immunization in  adjuvant followed by intravenous hyper- 
immunization before fusion (13). This immunization proto- 
col and  subsequent fusion were repeated eight times using 
bovine and  human clathrin as antigens with  no success  in 
producing additional clathrin-specific MAbs. The only MAbs 
produced from these fusions reacted with minor contaminants 
in the clathrin preparations used as antigen. These antibodies 
were isolated because they bound to the clathrin preparations 
in solid-phase RIA. This experience emphasized two points 
relevant to producing anti-clathrin MAbs.  First, it provided 
further evidence for the  poor antigenicity of the  clathrin 
molecule since even minor contaminants were more immu- 
nogenic. Second, it demonstrated the necessity of  using several 
independent tests to assay for clathrin-specific MAbs.  With 
these  points  in  mind,  the  footpad immunization  protocol 
described in this paper was chosen for production of anti- 
human brain clathrin MAbs.  This protocol has been previ- 
ously shown to be effective for producing antibodies that react 
with poorly immunogenic antigenic sites (17,  35). SJL mice 
were selected to be immunized because they have an abnor- 
mal immune system, which might favor production of anti- 
bodies to highly conserved proteins (36). Initial screening of 
the fusion included tests for antibody reactivity by solid-phase 
RIA, Western blot, and immunoprecipitation. This approach 
resulted in the production of three anti-clathrin MAbs recog- 
nizing previously undetected determinants. One MAb (X 16) 
reacts with the LC, light chain and in immunoprecipitation 
and soluble binding assays  has preferential affinity for free 
LC,. The other MAbs (X 19 and X22) react with two different 
clathrin heavy chain determinants. All three MAbs are of the 
IgGt isotype and react with both human and bovine clathrin. 
The X 16 MAb was compared with the CVC.6 MAb shown 
previously to be specific  for LC~ (13).  In this study it was 20  20  2 
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antibodies were iodinated and titered to determine a concentration sensitive to inhibition. 1251-antibody  at this concentration was 
tested for binding to bovine brain clathrin in the presence of decreasing amounts of unlabeled preparations of each antibody. 
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demonstrated  that,  in  solution,  CVC.6  reacts  with  heavy 
chain-associated LCa preferentially over free LCa. X I6 and 
CVC.6 also react with physically distinct sites on LC~, since 
they did not block each other in binding to LCa and could 
bind simultaneously to the antigen. The XI9 and X22 anti- 
bodies show similar specificity for clathrin heavy chain except 
for their reactivity in Western blot. The X 19 antibody recog- 
nizes a determinant that is labile after denaturation in SDS 
PAGE and transfer to nitrocellulose and is therefore distinct 
from the X22 determinant, which is still reactive under these 
conditions. Competition experiments with X 19, X22, CVC.4, 
and CVC.6 confirm that XI9 reacts with an antigenic site on 
the  clathrin  heavy chain  distinct  from the  X22  site.  X19 
binding influences CVC.4 binding, which is also affected by 
CVC.6  binding.  Since  CVC.6  binds  to  LC~, this  provides 
indirect evidence that the heavy chain determinant detected 
by X 19 may be close to the region where LC~ binds, in the 
proximal portion of the triskelion arm (13,  37, 38). 
MAbs that detect five different antigenic determinants on 
the clathrin molecule have been described in this paper. If  the 
MAbs reported by Louvard et at. (15)  and Kelly et al.  (16) 
are taken into account, at least seven different antigenic sites 
on the clathrin molecule have now been defined. It is inter- 
esting that an MAb to the LCb light chain has not yet been 
isolated. Nor has an antibody that reacts with both LCa and 
LCb  been  found.  Even  though  LCa  and  LCb have  a  very 
different primary structure,  as  indicated  by peptide  maps, 
they both bind to clathrin heavy chain and should have some 
antigenic features in common (14,  38,  39).  However, since 
heavy chain binding is an essential property of light chains, 
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be conserved and not very immunogenic. The high degree of 
conservation of clathrin structure and function between spe- 
cies as distant as yeast and humans is the most likely expla- 
nation  for  its  overall  poor  antigenicity  (40,  41).  For  this 
reason, production of anti-LCb MAbs and additional  anti- 
heavy chain MAbs may require immunization with separated 
clathrin polypeptides or with  chemically modified clathfin. 
With the production of  the three anti-clathrin MAbs described 
in this paper, it has become possible to carry out the accom- 
panying study of the forms of clathrin in vivo. Future expan- 
sion of the antibody panel will  make it possible to identify 
antigenic sites critical for clathrin assembly, look at the com- 
plete biosynthesis of the  molecule, and gain further insight 
into the regulation of clathrin-mediated processes. 
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